SEARCH

SEARCH BY CITATION

References

  • 1
    Hruban RH. Pancreatic cancer: from genes to patient care. J Gastro Intest Surg 2001; 5:5837.
  • 2
    Johnsen AK, Templeton DJ, Sy M, Harding CV. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999; 163:422431.
  • 3
    Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177:26572.
  • 4
    Alpan RS, Zhang M, Pardee AB. Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res 1996; 56:435861.
  • 5
    Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996; 13:2103.
  • 6
    Cromme FV, Airey J, Heemels MT et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:33540.
  • 7
    Cromme FV, Van Bommel PF, Walboomers JM et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994; 69:117681.
  • 8
    Johnsen A, France J, Sy MS, Harding CV. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 1998; 58:36607.
  • 9
    Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 1995; 55:51914.
  • 10
    Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 1994; 145:5059.
  • 11
    Keating PJ, Cromme FV, Duggan-Keen M et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72:40511.
  • 12
    Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer, 1996; 73:14853.
  • 13
    Kurokohchi K, Carrington M, Mann DL et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996; 23:11818.
  • 14
    Maeurer MJ, Gollin SM, Martin D et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98:163341.
  • 15
    Rowe M, Khanna R, Jacob CA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein–Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995; 25:137484.
  • 16
    Sanda MG, Restifo NP, Walsh JC et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995; 87:2805.
  • 17
    Seliger B, Hohne A, Knuth A et al. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 1996; 2:142733.
  • 18
    Seliger B, Hohne A, Knuth A et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996b; 56:175660.
  • 19
    Singal DP, Ye M, Ni J, Snider DP. Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett 1996; 50:14954.
  • 20
    Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58:73742.
  • 21
    Dotto GP, Parada LF, Weinberg RA. Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature 1985; 318:4725.
  • 22
    Kaklamanis L, Gatter KC, Hill AB et al. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 1992; 51:37985.
  • 23
    Torres MJ, Ruiz-Cabello F, Skoudy A et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumour derived cell line. Tissue Antigens 1996; 47:37281.
  • 24
    Lee JE, Abdalla J, Porter GA et al. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 2002; 9:58793.
  • 25
    Adams TE, Bodmer JG, Bodmer WF. Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens. Immunology 1983; 50:61324.
  • 26
    Watson AJ, DeMars R, Trowbridge IS, Bach FH. Detection of a novel human class II HLA antigen. Nature 1983; 304:35861.
  • 27
    Loiseau P, Lehn P, Dautry F et al. Correlation between an HLA-DQ alpha length polymorphism of messenger RNA and serologically defined specificities (DQw1, DRw53, DR3+5). Immunogenetics 1986; 23:11114.
  • 28
    Welsh K, Bunce M. Molecular typing for the MHC with PCR-SSP. Rev Immunogen 1999; 1:15776.
  • 29
    Scupoli MT, Sartoris S, Tosi G et al. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 1996; 48:30111.
  • 30
    Natali PG, Nicotra MR, Bigotti A et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 1989; 86:671923.
  • 31
    Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16:48794.
  • 32
    Momburg F, Degener T, Bacchus E, Moldenhauer G, Hammerling GJ, Moller P. Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 1986; 37:17984.
  • 33
    Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 1988; 5:20312.
  • 34
    Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2:4754.
  • 35
    Esteban F, Concha A, Huelin C et al. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 1989; 43:43642.
  • 36
    Gudmundsdottir I, Gunnlaugur Jonasson J, Sigurdsson H, Olafsdottir K, Tryggvadottir L, Ogmundsdottir HM. Altered expression of HLA class I antigens in breast cancer association with prognosis. Int J Cancer 2000; 89:5005.
  • 37
    Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A, B, C antigens on primary and metastatic tumour cell populations of human carcinomas. Cancer Res 1991; 51:637280.
  • 38
    Kamarashev J, Ferrone S, Seifert B et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001; 95:238.
  • 39
    Zimmer J, Andres E, Donato L, Hanau D, Hentges F, De La Salle H. Clinical and immunological aspects of HLA class I deficiency. Q J Med 2005; 98:71927.
  • 40
    Samukawa T. Expression of HLA-DR antigen on head and neck carcinomas − immunohistological study. 1993;96:8897.
  • 41
    Van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expreesion of HLA-DR, DQ and DP antigens in primary and metastatic melanoma. J Invest Dermatol 1988; 90:75560.